PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.

Abstract Studies have recommended a 21-gene recurrence score (RS) to optimize adjuvant treatment for patients with early-stage breast cancer (EBC) with hormone receptor-positive (HR(+)) and human epidermal growth factor receptor-2 negative (HER2(-)) tumors. This study aimed to prospectively evaluate the impact of this RS in Chinese patients with breast cancer.
PMID
Related Publications

Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.

Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.

The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

Authors

Mayor MeshTerms

Biomarkers, Tumor

Gene Expression Profiling

Keywords

21-gene score

Breast cancer

Ki67

adjuvant chemotherapy

early stage

Journal Title anticancer research
Publication Year Start



 
PMID- 28739750
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy 
      for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
PG  - 4539-4547
AB  - BACKGROUND: Studies have recommended a 21-gene recurrence score (RS) to optimize 
      adjuvant treatment for patients with early-stage breast cancer (EBC) with hormone
      receptor-positive (HR+) and human epidermal growth factor receptor-2 negative
      (HER2-) tumors. This study aimed to prospectively evaluate the impact of this RS 
      in Chinese patients with breast cancer. PATIENTS AND METHODS: We prospectively
      collected 227 patients with EBC with estrogen receptor-positive (ER+) and HER2-
      tumors. We used one-way analysis of variance to compare the distribution of
      different risk groups based on a 21-gene RS assay. A Kruskal-Wallis test and
      either a chi-square or Fisher's exact test were used as appropriate to compare
      continuous and categorical variables, respectively. RESULTS: Of the 227 eligible 
      women enrolled, 61.2%, 30%, and 8.8% of patients were in the low (&lt;/=17),
      intermediate (18-30) and high (&gt;/=31) RS groups, respectively. Of the patients
      with a low RS, 74.8% were overestimated into the intermediate-risk group by St.
      Gallen risk. The overall impact of the 21-gene RS was reduced use of chemotherapy
      (78/227, 34.4%). In addition, Ki67 expression was positively associated with the 
      21-gene RS (R=0.68). CONCLUSION: Among patients with ER+/HER2- EBC, the 21-gene
      RS was an effective method for making a chemotherapy decision. Ki67 was
      associated with 21-gene RS.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Zeng, Yinduo
AU  - Zeng Y
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Li, Qian
AU  - Li Q
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Qin, Tao
AU  - Qin T
AD  - Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, P.R. China.
FAU - Li, Shunrong
AU  - Li S
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Jin, Liang
AU  - Jin L
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Wu, Jiannan
AU  - Wu J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Chen, Kai
AU  - Chen K
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Deng, Heran
AU  - Deng H
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Rao, Nanyan
AU  - Rao N
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Liu, Qiang
AU  - Liu Q
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Su, Fengxi
AU  - Su F
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China.
FAU - Jia, Weijuan
AU  - Jia W
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China [email protected] [email protected]
FAU - Yao, Herui
AU  - Yao H
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
      Regulation, Breast Cancer Tumor Center, Sun Yat-sen Memorial Hospital, Sun
      Yat-sen University, Guangzhou, P.R. China [email protected] [email protected]
AD  - Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, P.R. China.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Biomarkers, Tumor
MH  - Breast Neoplasms/drug therapy/*genetics/pathology
MH  - Chemotherapy, Adjuvant/methods
MH  - Clinical Decision-Making
MH  - Female
MH  - *Gene Expression Profiling/methods
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - ROC Curve
MH  - Receptor, ErbB-2
MH  - Receptors, Estrogen/genetics
MH  - Receptors, Progesterone/genetics
MH  - Risk Factors
MH  - Tumor Burden
MH  - Young Adult
OTO - NOTNLM
OT  - 21-gene score
OT  - Breast cancer
OT  - Ki67
OT  - adjuvant chemotherapy
OT  - early stage
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/02 [received]
PHST- 2017/06/08 [revised]
PHST- 2017/06/13 [accepted]
AID - 37/8/4539 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4539-4547.